NPS+ Non Small Cell Lung Cancer (US) 2017
|NPS+:非小細胞肺癌 (美國) NPS+ Non Small Cell Lung Cancer (US) 2017|
|出版日期: 2017年07月01日||內容資訊: 英文||
本報告依據美國的100名癌症專門醫生的調查結果，提供非小細胞肺癌 (NSCLC)的領導品牌10項產品的醫生的使用趨勢和各種見解的比較、分析，支援客戶的忠誠度的NPS (淨推薦值) 指標的改善。
Which two US NSCLC brands are streets ahead of the competition?
There are various options available to US medical oncologists to treat non-small cell lung cancer (NSCLC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others - but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
NPS+ NSCLC (US) gives a unique insight into the overall brand health of 12 leading treatments for NSCLC currently being used in the US. 100 medical oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Interested in the European market? Click here to see the EU5 Edition.
Insight into 12 leading treatments for NSCLC
A Report Based on Expert Knowledge
We surveyed 100 US medical oncologists chosen from the largest community of validated physicians in the world.
We conducted the survey between 3rd and 13th July 2017.
Explore Important Brand Loyalty Issues
NPS+ NSCLC (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing small molecule and biologic treatments to patients with NSCLC. You'll discover:
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:
How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines "brand DNA", revealing in doctors' own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.